These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 17447208)

  • 1. Membrane-initiated steroid signaling action of estrogen and breast cancer.
    Song RX
    Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer.
    Song RX; Fan P; Yue W; Chen Y; Santen RJ
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S3-13. PubMed ID: 17259556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane initiated estrogen signaling in breast cancer.
    Song RX; Santen RJ
    Biol Reprod; 2006 Jul; 75(1):9-16. PubMed ID: 16571873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
    Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid receptors and their role in the biology and control of breast cancer growth.
    Cordera F; Jordan VC
    Semin Oncol; 2006 Dec; 33(6):631-41. PubMed ID: 17145341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.
    Lee AV; Cui X; Oesterreich S
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4429s-4435s; discussion 4411s-4412s. PubMed ID: 11916236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor: current understanding of its activation and modulation.
    Osborne CK; Schiff R; Fuqua SA; Shou J
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PubMed ID: 11916222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of hormone sensitivity for breast cancers.
    Miyoshi Y; Murase K; Saito M; Oh K
    Breast Cancer; 2010 Apr; 17(2):86-91. PubMed ID: 19806427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane-initiated steroid action in breast and prostate cancer.
    Kampa M; Pelekanou V; Castanas E
    Steroids; 2008 Oct; 73(9-10):953-60. PubMed ID: 18249430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensing estrogen's many pathways.
    Weatherman RV
    ACS Chem Biol; 2008 Jun; 3(6):338-40. PubMed ID: 18570353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
    Nicholson RI; Hutcheson IR; Britton D; Knowlden JM; Jones HE; Harper ME; Hiscox SE; Barrow D; Gee JM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):257-62. PubMed ID: 15860268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
    Massarweh S; Schiff R
    Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
    Staka CM; Nicholson RI; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S85-97. PubMed ID: 16113102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
    Thomas S; Munster PN
    Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
    Pietras RJ
    Oncologist; 2006; 11(7):704-17. PubMed ID: 16880230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crossroads of estrogen receptor and NF-kappaB signaling.
    Biswas DK; Singh S; Shi Q; Pardee AB; Iglehart JD
    Sci STKE; 2005 Jun; 2005(288):pe27. PubMed ID: 15956359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.
    Woodfield GW; Horan AD; Chen Y; Weigel RJ
    Cancer Res; 2007 Sep; 67(18):8439-43. PubMed ID: 17875680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.